Cabaletta Bio's shares rose nearly 6% to $2.33 in premarket trading, reflecting positive market sentiment regarding its clinical advancements.
The stock surged 11% following insider purchases by key executives, including General Counsel Michael Gerard and Chief Medical Officer Chang David J., indicating strong confidence in the company's future prospects. Additionally, the company's RESET program is making significant progress, with complete Phase 1/2 clinical data from the RESET-Myositis trial expected in 2025, further enhancing investor optimism.
These developments suggest a robust outlook for Cabaletta Bio, as insider confidence and clinical advancements are likely to attract further investor interest and support the stock's upward momentum.
Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 15.86 USD with a low forecast of 4.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 15.86 USD with a low forecast of 4.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.850
Low
4.00
Averages
15.86
High
30.00
Current: 2.850
Low
4.00
Averages
15.86
High
30.00
Morgan Stanley
Overweight
downgrade
$22 -> $14
2026-01-08
Reason
Morgan Stanley
Price Target
$22 -> $14
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Cabaletta Bio to $14 from $22 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Cantor Fitzgerald
Overweight
upgrade
$15 -> $30
2025-10-31
Reason
Cantor Fitzgerald
Price Target
$15 -> $30
2025-10-31
upgrade
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Cabaletta Bio to $30 from $15 and keeps an Overweight rating on the shares. Auto-CAR-T is showing unprecedented and transformational efficacy in scleroderma, and investors aren't appreciating how substantial this unmet need is, the analyst says in a research note, adding that bispecifics are also starting to look "good."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CABA
Unlock Now
Wells Fargo
Derek Archila
Equal Weight
downgrade
$3 -> $2
2025-08-08
Reason
Wells Fargo
Derek Archila
Price Target
$3 -> $2
2025-08-08
downgrade
Equal Weight
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Cabaletta Bio to $2 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the company's recent financing gives it time to gain more regulatory clarity for rese-cel in MG, SSc and SLE, but still falls short of its first BLA submission expected in 2027. Sentiment remains challenging and Wells expects shares to be range bound.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$25 -> $16
2025-08-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$25 -> $16
2025-08-08
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cabaletta Bio to $16 from $25 and keeps a Buy rating on the shares. The firm says accelerating enrollment lets rese-cel move towards registrational cohorts.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
